Elisabet Domínguez-Clavé
Psychologist and Doctor of Pharmacology, lecturer at the International University of La Rioja (UNIR) and president of the Spanish Society for Psychedelic Medicine (SEMPsi)
The most interesting aspect of this study is not so much that psilocybin ‘works’, but rather that it protects the nerves without producing any hallucinogenic effects and without compromising the effectiveness of chemotherapy against the tumour. However, the decisive step will be to conduct a clinical trial with patients to confirm that psilocybin does indeed prevent peripheral neuropathy. That would fill a very significant therapeutic gap.
This study provides the first robust evidence that psilocybin also acts directly on peripheral nerves – a completely unexplored area – thereby broadening the scope of application for this type of compound beyond psychiatry.
Psilocybin acts here like a vaccine; it does not repair a nerve that is already damaged, but prevents it from being damaged in the first place. This is a different strategy to that of current treatments and would involve administering it preventatively before each cycle of chemotherapy, rather than giving a painkiller to treat pain once it has set in.
What they propose is a rather elegant explanation: chemotherapy would not kill the neuron instantly, but would cut off the energy supply to the far end of the nerve, which would eventually die of starvation. Psilocybin would restore that energy supply.